List of investigational antipsychotics

This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

This list was last comprehensively updated in December 2017. It is likely to become outdated with time.

Receptor modulators

Monoamine receptor modulators

• Brilaroxazine (RP5063; oxaripiprazole) – atypical antipsychotic (D_2/3/4 and 5-HT_1A partial agonist and 5-HT_2A/2B/7 antagonist)
• FKF-02SC (TGOF-02N) – atypical antipsychotic (D₂ and 5-HT_2A receptor antagonist, other actions)
• Masupirdine (SUVN-502) – 5-HT₆ receptor antagonist
• N-Methylamisulpride (LB-102) – D_2,3, 5-HT₇, receptor antagonist (methylated version of amisulpride)
• Ralmitaront (RG-7906, RO-6889450) – TAAR1 agonist
• Ulotaront (SEP-856, SEP-363856) – 5-HT_1A receptor and TAAR1 agonist
• Usmarapride (SUVN-D4010) – 5-HT₄ receptor partial agonist

Glutamate receptor modulators

• Pomaglumetad methionil (DB-103, LY-2140023, LY-2812223) – mGluR₂ and mGluR₃ agonist
• Iclepertin – glycine transporter-1 inhibitor

Acetylcholine receptor modulators

• Emraclidine (CVL-231) – M₄ muscarinic acetylcholine receptor positive allosteric modulator.
• ML-007 – M₁ and M₄ muscarinic acetylcholine receptor agonist.
• NBI-1117568 (HTL 0016878) – M₄ muscarinic acetylcholine receptor agonist.
• NS-136 – M₄ muscarinic acetylcholine receptor positive allosteric modulator

Cannabinoid receptor modulators

• Cannabidiol (CBD; GW-42003, GWP-42003, GWP-42003-P, ECP-012A; Arvisol, Epidiolex) – cannabinoid receptor modulator, antioxidant, other actions

Other/mixed receptor modulators

• CVN766 – Orexin receptor type 1 antagonist
• Deudextromethorphan (d-DM; AVP-786, CTP-786) – σ₁ receptor agonist, serotonin–norepinephrine reuptake inhibitor, uncompetitive NMDA receptor antagonist, muscarinic acetylcholine receptor agonist, other actions
• Roluperidone (CYR-101, MIN-101, MT-210) – 5-HT_2A and σ₂ receptor antagonist
• TAK-041 (NBI 1065846) – GPR139 receptor agonist

Enzyme inhibitors

• Luvadaxistat (NBI 1065844, TAK-831) – D-amino acid oxidase inhibitor. (DAAO is a pathway to NMDAR.)
• MK-8189 – phosphodiesterase 10A inhibitor.
• Osoresnontrine (BI-409306, SUB-166499) – phosphodiesterase 9A inhibitor
• Sodium benzoate (SND-11, SND-12, SND-13, SND-14; Clozaben, NaBen) – D-amino acid oxidase inhibitor

Ion channel modulators

• Evenamide (NW-3509; NW-3509A) – Na_v1.3, Na_v1.7, and Na_v1.8 voltage-gated sodium channel blocker

Others

• Inidascamine (RL-007; FSV7-007) – undefined mechanism of action
• TS-134 (TS-1341) – undefined mechanism of action

See also

• List of investigational drugs

References

External links

• AdisInsight – Springer
• 2016 Medicines in Development for Mental Health – PhRMA